Ibopamine post-marketing surveillance. First report from a parallel-cohorts survey ongoing since April 1st, 1985.
Sher
D
D
Corporate Medical Department of Zambon Group S.p.A., Bresso-Milano Italy.
Ferrari
V
V
D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D003846:Deoxyepinephrine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004298:Dopamine / Q000031:analogs & derivatives*; D004347:Drug Interactions; D004562:Electrocardiography; D005069:Evaluation Studies as Topic; D005260:Female; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D011379:Prognosis; D012307:Risk Factors; D012737:Sex Factors; D012959:Socioeconomic Factors; D013923:Thromboembolism / Q000188:drug therapy
D002316:Cardiotonic Agents; C023487:ibopamine; D003846:Deoxyepinephrine; D004298:Dopamine